Abstract
Tinnitus, the perception of sound without the corresponding external stimulus, currently affects 15% of the US population. There is a critical need to unravel the heterogeneous etiologies underlying tinnitus and identify tailored treatment targets. Metabolomic studies have elucidated biological pathways underlying several neurodegenerative disorders and could identify metabolic perturbations that influence tinnitus development. We conducted the first large-scale metabolomic study to identify novel tinnitus biomarkers. We cross-sectionally evaluated plasma metabolite profiles and persistent tinnitus among 6477 women (488 with daily tinnitus ≥5 minutes and 5989 controls). A broad array of 466 metabolites was measured using liquid-chromatography mass spectrometry. Logistic regression was used to estimate odds ratios (OR, per 1 SD increase in metabolite values) and 95% confidence intervals (CI) for each individual metabolite while Metabolite Set Enrichment Analysis (MSEA) was used to identify metabolite classes enriched for associations with tinnitus; all models were adjusted for multiple comparisons. Compared with controls, homocitrulline (OR(95%CI)=1.32(1.16-1.50), C38:6 phosphatidylethanolamine (PE; 1.24(1.12-1.38)), C52:6 triglyceride (TAG; 1.22(1.10-1.36)), C36:4 PE (1.22(1.1-1.35)), C40:6 PE (1.22(1.09-1.35)), and C56:7 TAG (1.21(1.09-1.34)) were positively associated, whereas alpha-keto-beta-methylvalerate (0.68(0.56-0.82)) and levulinate (0.60(0.46-0.79)) were inversely associated with tinnitus (adjusted-p<0.05). Among metabolite classes, TAGs, PEs, and diglycerides (DAGs) were positively associated, while phosphatidylcholine (PC) plasmalogens, lysophosphatidylcholines (LPC), and cholesteryl esters were inversely associated with tinnitus (false discovery rate <0.05). This study identified novel plasma metabolites and metabolite classes that were significantly associated with persistent tinnitus. These findings extend our current understanding of tinnitus and could inform investigations of therapeutic targets for this challenging disorder.
Competing Interest Statement
This research was funded by the Royal National Institute for Deaf People (RNID) Grant G103_Curhan, Massachusetts Eye and Ear Foundation, Allan and Muriel Greenblatt Philanthropic Fund, Bertarelli Foundation Professorship and grants U01 DC010811, UM1 CA186107, P01 CA87969, R01 CA49449, R01 HL034594, R01 HL088521, R01 CA67262 and UO1 CA176726 from the National Institutes of Health. DBW reports being consult and/or on the Scientific Advisory Boards of Recursion Therapeutics, Inc, Science 24/7, NF2 BioSolutions, NF Bio, Daybreak Vision Project, Mulberry Therapeutics, Inc., Skylark Biotherapy, Inc., and Salubritus Bio, Inc. GCC reports being an employee of OM1, Inc, holding stock of Allena Pharmaceuticals, royalties (Section Editor and author) from UpToDate, and grant funding from Decibel Therapeutics.
Funding Statement
This research was funded by the Royal National Institute for Deaf People (RNID) Grant G103_Curhan, Massachusetts Eye and Ear Foundation, Allan and Muriel Greenblatt Philanthropic Fund, Bertarelli Foundation Professorship and grants U01 DC010811, UM1 CA186107, P01 CA87969, R01 CA49449, R01 HL034594, R01 HL088521, R01 CA67262 and UO1 CA176726 from the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Institutional Review Boards of the Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest: The authors declare that they have no conflict of interest.
Data Availability
The demographics and questionnaire data together with the plasma metabolomics profiles are not publicly available for the following reason: data contain information that could compromise research participant privacy. Reasonable requests to access these data should be made via http://www.nurseshealthstudy.org/researchers.
